Company: SHPH
Filing Date: 2025-12-11
Form Type: S-1/A
Source: 0001493152-25-027310
Chunk: 5

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-12-11
Form: S-1/A
Chunk 5
---
audiences.

The broader competitive
landscape in the AI ecosystem, especially AI-driven drug discovery, is rapidly advancing toward agentic AI systems and more integrated,
end-to-end platforms. To stay at the front of this shift, Molecule.ai is expanding its molecule predictive capabilities, and automated
multi-tool workflows. These expansions are designed in accordance with the agentic framework and multi-tool reasoning to further strengthen
the platform. A new module will evaluate chemical–protein interaction likelihoods, which will help researchers estimate how molecules
may interact with specific biological targets. Molecule.ai is adding biological context reasoning supported by curated genomic and disease-association
evidence, which helps tie together chemical ideas with the biological systems they may ultimately affect. The platform will increasingly
support insights that connect chemical properties with biological implications, which creates a more complete, end-to-end picture for
early research teams. Molecule.ai is also developing an autonomous AI agent designed to reduce manual workload and accelerate early research
cycles, which will interpret a discovery objective, plan a series of actions, route each step to the appropriate tools, evaluate preliminary
outputs and iterate until a stable result is achieved.

The Molecule.ai platform
adheres to strict engineering standards, including reproducibility, traceability, extensibility, scalability and interoperability, which
align with modern AI infrastructure expectations for regulated biomedical environments. Molecule.ai aims to become the foundational AI
layer for molecular and biological reasoning in pharmaceutical research and development. By integrating property prediction, biological
context, multi-step reasoning and agentic automation, the platform seeks to accelerate early discovery while maintaining scientific reliability
and operational transparency.

We are still evaluating
additional business impacts from the discontinuance of the Clinical Trials and the acquisition of Molecule.ai, all of which could materially
affect our plans and financial position.

Corporate Information

The Company was formed as a limited liability company in the state of Maryland in December 2012 and was converted to a C corporation in August 2016. In June 2018, we completed a share exchange with Shuttle Pharma Acquisition Corp. Inc. (“Acquisition Corp.”), pursuant to which Shuttle Pharmaceuticals, Inc. became a subsidiary of Acquisition Corp. and we subsequently changed the name of Acquisition Corp. to Shuttle Pharmaceuticals Holdings, Inc.

| 4 |

Our executive offices are located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879 and our telephone number is (240) 430-4212. Our corporate website is www.shuttle